Summary

Report Overview
The North America automated compounding devices market was valued at US$ 362.27 million in 2023 and is estimated to reach US$ 529.17 million by 2031, growing at a CAGR of 5.0% during the forecast period from 2024-2031
Automated compounding devices are sophisticated pharmaceutical equipment designed to automate and streamline the process of medication compounding. Medication compounding refers to the customized preparation of medications by pharmacists or trained pharmacy technicians to meet specific patient needs that cannot be met by commercially available products. This can include creating unique dosage forms, adjusting drug concentrations, or combining multiple medications into a single formulation. Automated compounding devices are typically used in settings such as hospitals, compounding pharmacies, long-term care facilities, and specialty clinics where precise medication doses and formulations are crucial for patient care. These devices utilize advanced technology, including robotics, automation, and software algorithms, to accurately measure, mix, and dispense medications in various forms, including intravenous (IV) solutions, oral liquids, topical creams, and ointments.
Market Dynamics
Rising Technological Advancements in Automated Compounding Devices
The automated compounding devices market is witnessing remarkable growth due to ongoing technological advancements that address key challenges and requirements in medication compounding. These advancements span various aspects of device design, functionality, and integration, driving market expansion and adoption rates. One of the primary drivers of market growth is the integration of enhanced safety features in automated compounding devices. Modern devices are equipped with sophisticated sensors, algorithms, and safety mechanisms to prevent errors and ensure compliance with medication compounding standards. For instance, advanced error detection systems can identify discrepancies in medication concentrations, volumes, or formulations, minimizing the risk of medication errors and adverse patient outcomes. Government journals and reports provide insightful statistics on the impact of automated compounding devices on medication safety. 
For instance, data from the U.S. Food and Drug Administration (FDA) indicate that medication errors contribute to approximately 7,000 deaths annually in the United States alone. However, hospitals and healthcare facilities adopting automated compounding devices have reported significant reductions in medication errors, with some studies indicating a reduction of up to 52%. Another significant trend driving market growth is the integration of robotics and artificial intelligence (AI) technologies in automated compounding devices. Robotics enable precise and consistent medication preparation, minimizing variability and ensuring uniformity in compounded products. AI algorithms analyze data, optimize compounding processes, and provide real-time feedback to pharmacy staff, enhancing operational efficiency and medication quality.
Market Segment Analysis
The North America automated compounding devices market is segmented based on Product Type, Source Type, Component type, Mode of operations, End Users and Country.
TPN (Total Parenteral Nutrition)
Total Parenteral Nutrition (TPN) in the global automated compounding devices market was valued at US$ 314.11 million in 2023 and are estimated to reach US$ 482.68 million by 2031, growing at a CAGR of 5.6% during the forecast period from 2024-2031. Total parenteral nutrition (TPN) compounding systems are specialized automated devices for preparing total parenteral nutrition solutions, which are critical for patients who cannot or should not receive their nutrition through oral or enteral routes. The need for TPN compounding systems is driven by the complexity of mixing various nutrients and the importance of adhering to stringent sterility and precise compositional requirements. These systems are essential in neonatology departments and intensive care units and for home-based long-term nutrition support. 
Prescribing and preparing total parenteral nutrition solutions is a complex process. Several systems have been developed, from standardized commercially available bags requiring minimal manipulation before infusion, to fully customized solutions compounded daily on-site. A compounded parenteral nutrition bag typically contains a mixture of more than 10 different solutions. Compounding these solutions requires experienced personnel (pharmacists and pharmacy technicians) and an adequate environment where microorganisms and air particles are minimized, because of a high risk of error and contamination during compounding, which can lead to serious adverse events and even patient deaths. Automated compounding devices have been purported to reduce the risk of human error and improve the efficiency of compounding compared with manual preparation.
Market Segmentation
By Product Type
Oral Liquid Compounding Systems
TPN (Total Parenteral Nutrition)
Compounding Systems
Chemotherapy Compounding Systems
By Source Type
Gravimetric Automated Compounding Devices*
Volumetric Automated Compounding Devices
Syringe-based Automated Compounding Devices
By Component
Hardware*
Software
Services
By Mode of Operation
Fully Automated Compounding Devices*
Semi-Automated Compounding Devices
By End-User
Hospitals*
Pharmacies
Others
By Country
U.S.
Canada
Mexico
Major Key players
Grifols, S.A. *
Baxter International Inc
COMECER S.p.A.
ARxIUM
ICU Medical Inc.
EQUASHIELD
B. Braun SE
BECTON, DICKINSON AND COMPANY
SMARTCOMPOUNDERS B.V.
NewIcon Oy
Why Purchase the Report?
To visualize the North America automated compounding devices market segmentation based on product type, technology, component, mode of operation, end-user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development. 
Excel data sheet with numerous data points of North America automated compounding devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.
The North America automated compounding devices market report would provide approximately 77 tables, 79 figures and 125 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Component
3.4. Snippet by Mode of Operation
3.5. Snippet by End-User
3.6. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Technological Advancements in Automated Compounding Devices
4.1.1.2. The Prevalence of Cancer
4.2. Restraints
4.2.1. The High Cost of ACD Systems
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Intravenous (IV) Compounding Systems *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Oral Liquid Compounding Systems
7.4. TPN (Total Parenteral Nutrition) Compounding Systems
7.5. Chemotherapy Compounding Systems
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
8.1.2. Market Attractiveness Index, By Technology
8.2. Gravimetric Automated Compounding Devices *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Volumetric Automated Compounding Devices
8.4. Syringe-based Automated Compounding Devices
9. By Component
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
9.1.2. Market Attractiveness Index, By Component
9.2. Hardware *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Software
9.4. Services
10. By Mode of Operation
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Operation
10.1.2. Market Attractiveness Index, By Mode of Operation
10.2. Fully Automated Compounding Devices*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Semi-Automated Compounding Devices
11. By End-User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Ambulatory Surgical Centers
11.4. Others
12. By Country
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.1.2. Market Attractiveness Index, By Country
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.2.3. Mexico
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Grifols, S.A *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Baxter International Inc
14.3. COMECER S.p.A.
14.4. ARxIUM
14.5. ICU Medical, Inc
14.6. Omnicell, Inc
14.7. EQUASHIELD
14.8. B. Braun Medical Inc
14.9. BECTON, DICKINSON, AND COMPANY
14.10. SMARTCOMPOUNDERS B.V. (*LIST NOT EXHAUSTIVE)
15. Appendix
15.1. About Us and Services
15.2. Contact Us